clinical trial · NCT07522099
Chinese Adults With Kidney Disease
ADARx Pharmaceuticals, Inc.·phase2·recruiting·n = 30
Immunoglobulin A Nephropathy (IgAN)Complement 3 Glomerulopathy (C3G)IC-MPGNADX-038Telitacicept
brief summary
This is a Phase 2 study to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics of ADX-038 in adults with complement-mediated kidney diseases. The study will enroll Chinese adults with IgA nephropathy, complement 3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN). The study will evaluate ADX-038 administered alone (Part A) and in combination with telitacicept (Part B).
started
Jul 23, 2026
primary completion
Jul 10, 2028
completion
Jan 21, 2029
last updated
Apr 22, 2026
official title
A Phase 2 Study to Assess ADX-038 in Chinese Adults With Complement-Mediated Kidney Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol